Comparing pevonedistat plus azacitidine versus azacitidine alone in patients with higher-risk MDS CMML or low-blast AML from up total population 2020 Watch Video
Preview(s): Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Your browser does not support playing the video.Please download the video!
Description: Prof Lionel Ades speaks to ecancer about a phase II study he presented at the ASCO 2020 virtual meeting, which investigated the combination of pevonedistat plus azacitidine versus azacitidine in patients with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukaemia (CMML), or low-blast acute myelogenous leukaemia (LB AML). nnHe describes the background of the study and outlines the design of the trial, which enrolled a total of 120 patients with higher-risk MDS/CMML or LB AML